Beone Medicines Ltd.

ONC · Nasdaq · ·

비교

US$415.95-1.0%11월 12일 종가

2026년 9월 30일까지의 수치 (2026년 11월 5일 제출 10-Q 기준)

1W: +2.2%
1M: +19.2%
3M

Beone Medicines Ltd. (ONC) 주식 — 좋은 사업일까? — InspectStocks

Beone Medicines Ltd.

ONC · Nasdaq · ·

비교

US$415.95-1.0%11월 12일 종가

2026년 9월 30일까지의 수치 (2026년 11월 5일 제출 10-Q 기준)

1W: +2.2%
1M: +19.2%
3M

Just reported

Q3 2026 results

From Beone Medicines's results release of 2026년 11월 5일; its quarterly report has since been filed.

Revenue
Actual
US$1.89B
+34% y/y
+11% q/q
Guided
—
No guide given
EPS, GAAP
Actual
US$3.25
+213% y/y
+56% q/q
Guided
—
No guide given
Operating income, GAAP
Actual
US$418.7M
+157% y/y
+29% q/q
Guided
—
No guide given

Company outlook

Full year 2026

RevenueUS$6.9B – US$7B+30% y/y First given
Operating income, adjustedUS$1.9B – US$2BFirst given
Operating income, GAAPUS$1.2B – US$1.3B+180% y/y First given

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Beone Medicines is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

Highest-graded in Biotechnology

Graded A or B and worth $2B or more: A first, then the largest.

All 355 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

어떻게 돈을 버는가

Sales of cancer medicines98%

매출 비중은 Q1 2026 기준 추정치이며, 제출된 보고서의 수치가 아닙니다.

경쟁 상대

무엇을 파는가6

BRUKINSA (zanubrutinib)
A pill for several blood cancers that blocks Bruton tyrosine kinase, a protein that helps certain cancer cells grow.
TEVIMBRA (tislelizumab)
An antibody treatment that blocks a signal cancer cells use to reduce the immune system's attack on them.
BEQALZI (sonrotoclax)
A pill that blocks the B-cell lymphoma 2 protein, which can help cancer cells survive; it is approved in the United States for certain mantle cell lymphoma patients.

3개 더 보기

XGEVA (denosumab)
An antibody medicine marketed by BeOne in China to help prevent bone complications in people with cancer and to treat giant cell tumor of bone.
BLINCYTO (blinatumomab)
A medicine marketed by BeOne in China for acute lymphoblastic leukemia that helps immune cells recognize and attack cancer cells.
KYPROLIS (carfilzomib)
A medicine marketed by BeOne in China for multiple myeloma that interferes with a process cancer cells use to dispose of unwanted proteins.

누가 사는가2

Commercial distributors and other medicine buyers purchase BeOne's products for sale or supply to treatment providers.
Government health systems and private insurers decide which medicines they cover and reimburse; patients receive the medicines through their cancer care.

무엇에 기대고 있고, 무엇이 무너뜨릴 수 있는가

사업이 기대고 있는 것

1A large share of sales comes from BRUKINSA, so its continued use by doctors and patients and its coverage by health systems and insurers matter to revenue.
2Sales depend on government and private reimbursement, including coverage decisions and negotiated medicine prices in China and other markets.
3For licensed medicines such as XGEVA, BLINCYTO and KYPROLIS, BeOne depends on partner agreements and partner or contract manufacturers for supply.
4BeOne relies on some outside manufacturers, suppliers and research contractors for medicines, materials and development work.

잘못될 수 있는 일

1Clinical trials may not show that medicines work or are safe enough for regulators to approve them; delays, trial failures or safety problems could prevent new medicines or uses from reaching patients.
2Competition from medicines such as IMBRUVICA, CALQUENCE and KEYTRUDA, along with changes in coverage, reimbursement or medicine pricing, could reduce sales or patient access.
3BeOne operates across China, the United States and other markets, so changes in government policy, regulation or trade relations can affect approvals, manufacturing, sales and the movement of money.

전체 재무제표 보기 →

Beone Medicines Ltd. 소개

BeOne Medicines discovers, develops, makes and sells treatments for cancer. Its main medicine, BRUKINSA (zanubrutinib), is a pill that blocks Bruton tyrosine kinase, a protein involved in some blood cancers. It also sells TEVIMBRA, an antibody that blocks a signal cancers use to dampen immune attacks, and markets licensed cancer medicines in China.

본사: Basel, Switzerland
설립: 2010
임직원 수: More than 12,000 (Q2 2026, medium)
상장 시장: Nasdaq
회계연도 종료: December 31

Beone Medicines Ltd.이(가) 미국 증권거래위원회(SEC)에 직접 제출한 공시로 만들었습니다. 수치는 보고된 그대로이며, 주당 이력은 오늘의 주식 수 기준으로 재계산했습니다. 이것은 사업을 설명하는 자료입니다. 투자 자문이 아니며 어떤 매수나 매도도 권유하지 않습니다.

Just reported